What question did this study set out to answer?

The review aims to evaluate the effectiveness of immunomodulatory therapies for Graves’ ophthalmopathy.

February 13, 2026Frontiers in Endocrinology0 citationsOpen Access

Immunomodulators in Graves’ ophthalmopathy: a systematic review

AYAntoinette YeungUniversity Hospitals Birmingham NHS Foundation Trust MSMohammed Saqlain SiddiquiNational Health Service NMNeginsadat MirtorabiUniversity Hospitals Birmingham NHS Foundation Trust

Key Points

The review aims to evaluate the effectiveness of immunomodulatory therapies for Graves’ ophthalmopathy.
Databases searched included Cochrane, Embase, MEDLINE, ProQuest, PubMed, SCOPUS, and Web of Science.
Eligibility included studies on humans with Graves’ ophthalmopathy treated with targeted immunomodulatory therapies.
A narrative synthesis focused on clinical activity score and secondary outcomes was performed.
Cochrane risk of bias tools assessed study quality.
41 studies were eligible for data extraction from 4839 records identified.
Teprotumumab and tocilizumab significantly reduced clinical activity score and proptosis.
Rituximab's effectiveness was inconclusive; methotrexate showed benefits in reducing clinical activity score.
Adverse events were higher in the steroid-treated group compared to other drugs.

Abstract

Background Graves’ Ophthalmopathy (GO), or thyroid eye disease, is an extrathyroidal complication of Graves’ disease, causing a significant impact on patients’ quality of life. There are consensus statements from both the American Thyroid Association (ATA) and the European Group on Graves’ Orbitopathy (EUGOGO) which provide guidance in management. However, there remain areas of ongoing debate and evolution in treatment approaches. This systematic review aims to evaluate immunomodulatory drugs in the treatment of GO. Methods The following databases were searched: Cochrane (CENTRAL), Embase, MEDLINE, ProQuest, PubMed, SCOPUS, and Web of Science. The last date of searching for each database was 10th October 2025. All primary studies on human patients with GO, treated with newer, targeted immunomodulatory therapies, in particular biologics and/or disease-modifying antirheumatic drugs, were included. Studies in languages other than English were excluded. The primary outcome of interest was Clinical Activity Score (CAS). A narrative synthesis was performed, including CAS and four other secondary outcomes. Cochrane risk of bias tools were used to assess quality of evidence. The study is registered on PROSPERO (CRD42023400285). Results Of 4839 records identified, 41 were eligible for data extraction. Teprotumumab and tocilizumab showed benefit in reducing CAS and proptosis, whilst rituximab was inconclusive. Methotrexate and reduced-dose steroids were beneficial in reducing CAS, and both methotrexate and cyclosporine with steroids were good for reducing proptosis. However, effects of immunomodulation on other secondary outcomes were unclear. Adverse events were higher in the steroid treated patients compared to all other drugs. Conclusion Biologics and steroid-sparing agents may be more effective than steroids at reducing CAS, but this is limited by the lack of head-to-head comparisons between drugs and significant heterogeneity amongst the included studies. Systematic Review Registration https://www.crd.york.ac.uk/prospero/ , identifier CRD42023400285.

Ask AI

Helpful

Bookmark

View Full Paper